Commentary on: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION)
Saurat JH, Stingl G, Dubertret L, et al
Br J Dermatol. 2008;158(3):558-566
Question: How effective and safe is adalimumab compared with methotrexate in patients with moderate to severe psoriasis?
Design: Noninferiority randomized controlled trial.